This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?
by Ekta Bagri
At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide portfolio, upcoming product launches, promising pipeline candidates and recent positive estimate revisions
GSKNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline
by Zacks Equity Research
bioAffinity's first-quarter 2025 results show CyPath Lung sales growth and cost cuts despite a drop in total revenues and a wider quarterly net loss.
BIAFPositive Net Change
biotechnology biotechs earnings medical
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies
by Zacks Equity Research
CRSP enters into a strategic partnership with Sirius Therapeutics for developing novel siRNA Therapies.
VRTXNegative Net Change HALONegative Net Change AMRNPositive Net Change CRSPPositive Net Change
biotechs
REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research
by Zacks Equity Research
Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.
REGNNegative Net Change BAYRYNegative Net Change HALONegative Net Change ALLONegative Net Change
biotechnology biotechs dna-sequencing genomics medical pharmaceuticals
Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?
by Ekta Bagri
At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.
BMYNegative Net Change AMGNNegative Net Change
biotechnology biotechs cancer medical pharmaceuticals
Novo Nordisk Shares Dip 3% on Sudden CEO Transition Announcement
by Zacks Equity Research
NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine
by Zacks Equity Research
The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new conditions.
SNYNegative Net Change PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent
by Zacks Equity Research
Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.
BAYRYNegative Net Change HALONegative Net Change ACADNegative Net Change NTLANo Net Change
biotechnology biotechs medical pharmaceuticals
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz
by Zacks Equity Research
BMRN's acquisition of INZY is set to add a late-stage enzyme replacement therapy for a rare genetic condition. The deal is likely to be closed by September.
BMRNNegative Net Change AGENNegative Net Change ADPTNegative Net Change
biotechs medical pharmaceuticals
Incyte Gets FDA Approval for Zynyz in New Cancer Indication
by Zacks Equity Research
The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.
NVSNegative Net Change INCYNegative Net Change HALONegative Net Change NTLANo Net Change
biotechs
Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?
by Ahan Chakraborty
Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD reports a wider-than-expected loss for the first quarter of 2025. The company provides updates regarding its pipeline development plans.
HALONegative Net Change KODNegative Net Change ALLONegative Net Change
biotechs earnings
Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock
by Ahan Chakraborty
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
SNYNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change RXRXNegative Net Change
artificial-intelligence biotechnology biotechs medical pharmaceuticals
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk
by Zacks Equity Research
SEPN is entitled to receive around $2.2 billion from NVO under the new collaboration deal, which aims to develop oral pills for obesity and other diseases.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change SEPNNegative Net Change
biotechs pharmaceuticals
AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer
by Zacks Equity Research
Following the approval, ABBV's Emrelis becomes the first FDA-approved therapy for previously treated advanced NSCLC patients with high c-Met protein overexpression.
ABBVNegative Net Change AGENNegative Net Change ADPTNegative Net Change
biotechs medical pharmaceuticals
5 Low Price-to-Book Value Stocks to Buy in May
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and SAN are some such stocks.
PFENegative Net Change CVSPositive Net Change CNCNegative Net Change SANNegative Net Change STNEPositive Net Change
biotechs medical pharmaceuticals
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug
by Zacks Equity Research
Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.
GSKNegative Net Change NVSNegative Net Change
biotechs medical pharmaceuticals
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus
by Zacks Equity Research
FATE incurs a narrower-than-expected loss in the first quarter. The company's innovative pipeline remains in focus.
HALONegative Net Change FATENegative Net Change ALLONegative Net Change
biotechs earnings
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line
by Zacks Equity Research
Exelixis' first-quarter earnings and sales beat estimates as lead drug Cabometyx maintains momentum. The company raises its sales guidance for 2025.
BAYRYNegative Net Change EXELPositive Net Change EDITNegative Net Change ALLONegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
by Zacks Equity Research
ALLO's first-quarter earnings match estimates. Devoid of marketed products, the company records nil sales in the quarter.
AGENNegative Net Change ADPTNegative Net Change ALLONegative Net Change
biotechs cell-therapy earnings medical
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE incurs narrower-than-estimated first-quarter 2025 loss. Studies on lead candidate, azetukalner, in epilepsy and MDD are progressing well.
HALONegative Net Change NBIXNegative Net Change XENENegative Net Change ALLONegative Net Change
biotechs earnings
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Hurts Sales
by Zacks Equity Research
BAYRY's first-quarter earnings beat expectations. Revenues miss estimates, mainly due to lower sales of its products in the Crop Science division.
REGNNegative Net Change AZNNegative Net Change JNJNegative Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
EDIT announces encouraging first-quarter 2025 results, as both earnings and revenues beat estimates.
AZNNegative Net Change BAYRYNegative Net Change EDITNegative Net Change ALLONegative Net Change
biotechnology biotechs crispr earnings medical pharmaceuticals
RHHBY to Invest $1.25B to Boost Manufacturing Footprint in US
by Zacks Equity Research
Roche plans to invest over $700 million in setting up a new plant in North Carolina and up to $550 million in expanding its Indianapolis diagnostics hub.
NVSNegative Net Change RHHBYNegative Net Change JNJNegative Net Change LLYNegative Net Change
biotechs medical pharmaceuticals
Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared
by Kinjel Shah
President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices.
PFENegative Net Change MRKNegative Net Change LLYNegative Net Change AMGNNegative Net Change ABBVNegative Net Change
biotechs pharmaceuticals